



THE UNIVERSITY *of* EDINBURGH

Edinburgh Research Explorer

Prostaglandin E2 stimulates adaptive IL-22 production and promotes allergic contact dermatitis

Citation for published version:

Robb, CT, McSorley, HJ, Lee, J, Aoki, T, Yu, C, Crittenden, S, Astier, A, Felton, JM, Parkinson, N, Ayele, A, Breyer, RM, Anderton, SM, Narumiya, S, Rossi, AG, Howie, S, Guttman-Yassky, E, Weller, RB & Yao, C 2017, 'Prostaglandin E2 stimulates adaptive IL-22 production and promotes allergic contact dermatitis', *Journal of Allergy and Clinical Immunology*, vol. 141, no. 1, pp. 152-162.
<https://doi.org/10.1016/j.jaci.2017.04.045>

Digital Object Identifier (DOI):

[10.1016/j.jaci.2017.04.045](https://doi.org/10.1016/j.jaci.2017.04.045)

Link:

[Link to publication record in Edinburgh Research Explorer](#)

Document Version:

Peer reviewed version

Published In:

Journal of Allergy and Clinical Immunology

Publisher Rights Statement:

Copyright © 2017 Elsevier Inc. All rights reserved.

General rights

Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy

The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.



Title page**Original Article****Prostaglandin E₂ stimulates adaptive IL-22 production and promotes allergic contact dermatitis**

Calum T. Robb, PhD,^a Henry J. McSorley, PhD,^a Jinju Lee, MSc^{b,c} Tomohiro Aoki, MD, PhD^{b,c} Cunjing Yu, PhD,^a Siobhan Crittenden, MSc,^a Anne Astier, PhD,^a Jennifer Felton, PhD^a Nicholas Parkinson, MA, MS, VetMB^a Adane Ayele, MD,^d Richard M. Breyer, PhD,^{e,f} Stephen M. Anderton, PhD,^a Shuh Narumiya, MD, PhD,^{b,c} Adriano G. Rossi, PhD, DSc^a Sarah E. Howie, PhD,^a Emma Guttman-Yassky, MD, PhD,^{g,h} Richard B. Weller, MD, FRCP,^a Chengcan Yao, PhD,^a

^a Medical Research Council (MRC) Centre for Inflammation Research, Queen's Medical Research Institute, The University of Edinburgh, Edinburgh EH16 4TJ, UK.

^b Center for Innovation in Immunoregulative Technology and Therapeutics (AK Project), Kyoto University Graduate School of Medicine, Kyoto 606-8501, Japan.

^c Core Research for Evolutional Science and Technology, Medical Innovation Center, Kyoto University Graduate School of Medicine, Kyoto 606-8507, Japan.

^d Department of Dermatovenereology, School of Medicine, College of Health Sciences, Addis Ababa University, Addis Ababa, Ethiopia.

^e Department of Veterans Affairs, Tennessee Valley Health Authority, Nashville, TN 37212, USA.

^f Department of Medicine, Vanderbilt University Medical Center, Nashville, TN 37232, USA.

^g Department of Dermatology and the Laboratory for Inflammatory Skin Diseases, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA

^h Laboratory for Investigative Dermatology, The Rockefeller University, NY 10065, USA

Corresponding author

Chengcan Yao, PhD

Medical Research Council (MRC) Centre for Inflammation Research,

Queen's Medical Research Institute,

The University of Edinburgh,

47 Little France Crescent

Edinburgh EH16 4TJ, UK.

Telephone: +4413-1242-6685

Fax: +4413-1242-6578

Email: Chengcan.Yao@ed.ac.uk

Funding:

This work was supported in part by the University of Edinburgh start-up funding and Wellcome Trust Institutional Strategic Support Fund (to C.Yao and H.J.M.), Asthma UK (to H.J.M.), Psoriasis Association UK (to R.B.W.), Medical Research Council (MRC) UK (A.G.R. C.T.R. and J.M.F. were supported by MR/K013386/1, and to S.M.A., R.B.W. and H.J.M.), NIH DK37097 and R56HL127218 and a VA Merit 1BX000616 (to R.M.B.), and Core Research for Evolutional Science and Technology (CREST) of Japan Science and Technology Agency (to S.N.). C.Yu and C.S. receive scholarship supports from the Chinese

Scholarship Council and the University of Edinburgh, respectively. N.P. is supported by the Wellcome Trust Edinburgh Clinical Academic Training Programme.

Acknowledgements:

We thank P. Ghazal (The University of Edinburgh) for critically reading and editing the manuscript and S. Johnston, W. Ramsay and F. Rossi for assistance with flow cytometry.

Disclosure of potential conflict of interest:

The authors declare that they have no relevant conflicts of interest.

Abstract

Background: Atopic dermatitis (AD) is a chronic inflammatory skin disease with a central role of Th22-derived IL-22 in its pathogenesis. Although prostaglandin E₂ (PGE₂) is known to promote inflammation, little is known about its role in processes related to AD development, including IL-22 up-regulation.

Objectives: To investigate whether PGE₂ has a role in IL-22 induction and development of allergic contact dermatitis (ACD), a disease related to AD.

Methods: T-cell cultures and *in vivo* sensitization of mice with hapten were used to assess the role of PGE₂ in production of IL-22. The involvement of PGE₂ receptors and their downstream signals were also examined. The effects of PGE₂ were evaluated using the oxazolone (OXA)-induced ACD mouse model. The relationship of PGE₂ and IL-22 signaling pathways were also investigated using genomic profiling in human lesional AD skin.

Results: PGE₂ induces IL-22 from T cells through its receptors EP2 and EP4 and involves cyclic adenosine monophosphate (cAMP) signaling. Selective deletion of EP4 in T-cells prevents hapten-induced IL-22 production *in vivo*, and inhibition of PGE₂ synthesis limits atopic-like skin inflammation in the OXA-induced ACD model. Moreover, both PGE₂ and IL-22 pathway genes were coordinately up-regulated in human AD lesional skin, but were below significant detection levels after corticosteroid or ultraviolet band B (UVB) treatments.

Conclusions: Our results define a crucial role for PGE₂ in promoting ACD by facilitating IL-22 production from T-cells.

85 Clinical Implications: (<30 words)

86 Atopic dermatitis is a common disabling disease characterized by elevated IL-22. The
87 identification of a tightly regulated PGE₂ driven pathway controlling IL-22 dysfunction offers
88 a novel target for therapeutic intervention.

89

90 Capsule Summary: (<35 words)

91 Prostaglandin E₂ promotes IL-22 production from T cells that mediates IL-22-driven
92 development of atopic dermatitis.

93

94 Key words

95 Atopic dermatitis, Prostaglandin E₂, CD4⁺ T cells, Th22 cells, Th17 cells, Interleukin 22,

96 Abbreviations used

97 ACD: Allergic contact dermatitis

98 AD: Atopic dermatitis

99 AHR: Aryl hydrocarbon receptor

100 ANOVA: Analysis of variance

101 cAMP: Cyclic adenosine monophosphate

102 CCR: Chemokine receptor

103 COX: Cyclooxygenases

104 Db-cAMP: Dibutyryl cAMP

105 DC: Dendritic cell

106 DNFB: Dinitrofluorobenzene

107 IL-22: Interleukin 22

108 ILC3: Group 3 innate lymphoid cells

109 LN: Lymph node

- 110 mPGES: Microsomal prostaglandin E synthases
- 111 OXA: Oxazolone
- 112 PGE₂: Prostaglandin E₂
- 113 PKA: Protein kinase A
- 114 Th: Helper T cells
- 115 UVB: Ultraviolet band B

Introduction

Atopic dermatitis (AD) is a common chronic inflammatory skin disease, with a prevalence of up to 3-7% in adults and up to 25% among children^{1,2}. Histologic features of affected eczematous skin include epidermal hyperplasia and spongiosis, and infiltration of immune cells (T-cells, dendritic cells/DCs, eosinophils, etc) in the dermis^{1,3,4}. Barrier dysfunction is also recognized as important for development of AD⁵⁻⁷. Environmental allergens can penetrate through the skin in AD due to a dysfunctional epidermal barrier, where they are taken up by antigen presenting cells (such as dendritic cells) which in turn activate and polarize T-cells, resulting in AD initiation¹. Dysregulation of the balance of type 1 and 2 helper T (Th1 and Th2) cells, characterized by production of IFN- γ or IL-4/IL-13, respectively, has traditionally been thought to contribute to AD pathogenesis⁸. However, recent studies have shown that IL-17 and IL-22, produced by Th17 and other activated T cells including Th22 cells, are also critical in mediating the initiation and progression of AD⁹⁻¹³. IL-22 levels in serum from patients with AD are higher than those from healthy individuals^{14,15}, and IL-22⁺ T cells infiltrate into lesional AD skin¹⁶ where IL-22 induces epidermal hyperplasia and inhibits epidermal differentiation^{17,18}. Importantly, a neutralizing anti-IL-22 antibody (NCT01941537) or targeting components of the IL-23/Th17 pathway, are currently being tested in clinical trials^{3,19}. To refine future therapies, there is a need to better understand the mechanisms that drive IL-22 production in response to cutaneous antigen stimulation.

Prostanoids, including prostaglandin D₂ (PGD₂), PGE₂, PGF_{2 α} , PGI₂ and thromboxane A₂, are bioactive lipid mediators that are generated from arachidonic acid by cyclooxygenases (COX) and then respective PG synthases. PGs have various roles in inflammatory skin diseases through regulating functions of immune cells, including Th1/Th17 T-cells, T regulatory cells, mast cells and DCs²⁰. PGE₂ is synthesized by

microsomal prostaglandin E synthases (mPGES1 and mPGES2) and has essential roles in modulating various inflammatory responses by binding to PG receptors (EP1-4) on cell surfaces. Many cutaneous cells, including keratinocytes, mast cells, eosinophils, fibroblasts, DCs and lymphocytes, express PGs and PG receptors²¹. Increased PGE₂ expression in biologically active amounts has been reported in both lesional and non-lesional skin from AD patients²². Blockade of PG production by a COX2 inhibitor was reported to enhance eosinophil infiltration and elevate IL-4 expression in lesions of an OVA-sensitized mouse model²³. In contrast, PGE₂ was also suggested to induce AD by favoring a Th2 immune milieu and directly enhancing B-cell production of IgE^{24,25}. Furthermore, we and others have recently reported that PGE₂ through EP2 and EP4 receptors augmented IL-17 and IL-22 productions, and blockade of PGE₂ signaling during T-cell differentiation limited acute contact hypersensitivity²⁶⁻²⁸. These findings suggest that PGE₂ may have both suppressive and provocative roles in the development of AD²¹. However, it is unclear how PGE₂ regulates IL-22 production and chronic, atopic skin inflammation.

Here we report that PGE₂ promotes IL-22 production from Th17 and Th22 T-cells through its receptors EP2 and EP4. This effect is mediated by cAMP-protein kinase A (PKA) signaling and induction of aryl hydrocarbon receptor (AHR), a transcription factor critical for both adaptive and innate IL-22 expression²⁹. T-cell specific EP4 deficiency diminishes hapten-induced IL-22-expressing T cells in skin-draining lymph nodes (LNs). Accordingly, inhibition of PGE₂ production limits skin inflammation in an animal model for ACD induced by repeated OXA challenges in mice. Furthermore, genes related to PGE₂ signaling are over-expressed in human atopic lesional skin, and positively correlate with expression of IL-22 pathway genes. This relationship between expression of PGE₂ and IL-22-related genes is no longer evident after successful corticosteroid or UVB treatments. These findings suggest that PGE₂ facilitates ACD through promoting adaptive IL-22 signaling.

Methods

Mice

Wild-type C57BL/6 mice were purchased from Harlan UK. Lck-Cre mice were crossed to lox-flanked *Ptger4* (EP4-floxed) mice³⁰ to generate mice with selective EP4 deficiency in T cells (EP4cKO) as previously reported^{27,28}. All mice were bred and maintained under specific pathogen-free conditions in accredited animal facilities in the University of Edinburgh and Kyoto University. Mice were aged >7 weeks old at the beginning of use and sex-matched. All experiments were conducted in accordance with the UK Scientific Procedures Act of 1986 and had local institutional ethical approval.

Reagents

Antibodies to mouse CD3 (clone 145-2C11), CD28 (clone 37.51), CD45 (clone 30-F11), CD4 (clone L3T4), CD8 (clone 53-6.7), IL-17A (clone eBio17B7), IL-22 (clone IL22J0P) and to human CD3 (clone OKT3) and IL-22 (clone 142928) were from eBioscience or Biolegend. Anti-human IL-22 was from R&D Systems. Mouse CD4 microbeads were from Miltenyi Biotec. Recombinant human TGF- β 1 and recombinant mouse IL-6 and IL-23 were purchased from Biolegend. PGE₂, 17-phenyl trinor PGE₂ (EP1/3 agonist), Butaprost (EP2 agonist), CAY10598 or L-902,688 (EP4 agonist), PF-04418948 (EP2 antagonist), and L-161,982 (EP4 antagonist) were from Cayman. Db-cAMP, PKA Inhibitor 14-22 (PKI), CH-223191, oxalozone, indomethacin, phorbol myristate acetate (PMA), Ionomycin were from Sigma or Calbiochem.

Oxazolone-induced ACD model

The OXA-induced mouse ACD model was induced as reported¹¹. Briefly, mice were sensitized with 3% OXA in EtOH on shaved abdominal skin and after 5 days were repeatedly

challenged with 0.6% OXA in EtOH on one ear once every two days for a total of 5 challenges. The opposing ear was challenged with vehicle (pure EtOH) to serve as a control. Mice were culled at 6 h after the last challenge and the ears and ear-draining LNs collected for further analysis. Ear samples were fixed with 10% neutral buffered formalin solution (Sigma), embedded in paraffin wax, and 5µm sections used for staining with hematoxylin and eosin (H&E). In some experiments, EP4cKO or control mice were sensitized with 0.5% dinitrofluorobenzene (DNFB), and 5 days later skin-draining LNs were collected for further analysis.

T-cell isolation and culture

Mouse CD4⁺ T-cells were isolated from spleens using autoMACS (Miltenyi). Cells were cultured in complete RPMI1640 medium containing 10% FBS and stimulated with plate-bound anti-CD3 (5 µg/ml) and anti-CD28 (5 µg/ml) antibodies plus various cytokines and other compounds as indicated in figures. For certain experiments, Th17 cells were differentiated from CD4⁺ T-cells by TGF-β1 and IL-6 for 3-4 d. IL-22 levels in supernatants were measured using mouse IL-22 enzyme-linked immunosorbent assay (ELISA) Ready-SET-Go![®] kits (eBioscience).

Surface and intracellular staining

For surface staining, cells were stained on ice for 30 min with anti-CD45, anti-CD3e, anti-CD4 and anti-CD8 Abs. For intracellular staining of IL-22, cells were stimulated with PMA and ionomycin for 4-5h in the presence of GolgiPlug (BD Bioscience). Cells were then harvested and fixed by BD Cytofix/Cytoperm Fixation Buffer (BD Bioscience) for 30min and then stained with anti-human/mouse IL-22 (clone IL22JOP, eBioscience) or anti-human

IL-22 in BD Perm/Wash Buffer for 1h. Flow cytometry was performed on a BD LSRFortessa (BD Bioscience) and analyzed by FlowJo software (Tree Star).

Real-time PCR

RNA purification from T-cells was performed using the Rneasy Mini Kit (Qiagen). cDNA was obtained by reverse transcription using High-capacity cDNA Reverse Transcription Kits (ABI). Samples were analyzed by real-time PCR with SYBR Premix Ex Taq II (Tli RNase H Plus) kit (Takara) or GoTaq qPCR Master Mix (Promega) on the Applied Biosystem 7900HT Fast machine. The following primers were used. *Gapdh* forward, 5'-TGAACGGGAAGCTCACTGG-3'; *Gapdh* reverse, 5'-TCCACCACCCTGTTGCTGTA-3'. *Il22* forward, 5'-CATGCAGGAGGTGGTACCTT-3'; *Il22* reverse, 5'-CAGACGCAAGCATTCTCAG-3'. *Ahr* forward, 5'-TGCACAAGGAGTGGACGA-3'; *Ahr* reverse, 5'-AGGAAGCTGGTCTGGGGTAT-3'. *Ccr4* forward, 5'-TGTCCTCAGGATCACTTTCAGA-3'; *Ccr4* reverse, 5'-GGCATTTCATCTTTGGAATCG-3'. Expression was normalized to mouse glyceraldehyde-3-phosphate dehydrogenase (*Gapdh*) and presented as relative expression to control group by the $2^{-\Delta\Delta Ct}$ method.

Gene expression of human skin biopsies from microarray datasets

Microarray gene expression data of human skin biopsies were retrieved from Gene Expression Omnibus datasets (GSE16161, GSE32924, GSE36842, GSE32473 and GSE27887)³¹⁻³⁵. Patients information and skin sample have been described previously^{31-33,35}. In brief, skin biopsy specimens were collected from patients with moderate-to-severe AD (Scoring of Atopic Dermatitis 20-97) and healthy volunteers under institutional review board-approved protocols (written consent obtained). Patients (age 16-81, mean age 40 from three cohorts) with an acute exacerbation of chronic AD and without any therapy for more

than 4 weeks were included. Biopsy specimens were obtained from acute lesional skin which was actively involved, and erythematous lesions with atopic dermatitis and were frozen in liquid nitrogen for RNA extraction^{31-33,35}. To standardize data across a wide range of experiments and to allow for the comparison of microarray data independent of the original hybridization intensities, gene expression levels were transformed to z-score values³⁶. *P* values were calculated by nonparametric Wilcoxon-Mann-Whitney test, paired nonparametric tests with post-hoc Dunn's multiple comparisons or paired 2-way analysis of variance (ANOVA) test with post-hoc Bonferroni's multiple comparisons test. Correlations between expression levels of two genes were calculated by nonparametric Spearman correlation test.

Statistical analyses

All data were expressed as mean \pm SEM or scatter dot-plots in which each dot represents one mouse, one AD patient or healthy individual. Statistical significance between two groups was examined by the Student's *t*-test or Mann-Whitney test, while the one-way and two-way ANOVA with post-hoc Bonferroni's multiple comparisons test were used to evaluate multiple groups unless otherwise indicated in figure legends. Statistical analyses were performed using Prism 6 software (GraphPad) and a *P*<0.05 was considered as statistically significant.

Results

PGE₂ promotes IL-22 production *in vitro* through its receptors EP2 and EP4

We have recently reported that PGE₂ promotes IL-22 production from group 3 innate lymphoid cells (ILC3s)²⁸. We thus evaluated whether PGE₂ also promoted IL-22 production from T-cells. To address this question, we isolated CD4⁺ T-cells from mouse spleens, activated with anti-CD3 and anti-CD28 antibodies (Abs), and co-cultured with various cytokines. Addition of exogenous PGE₂ enhanced *Il22* gene expression with IL-6 or IL-23 alone, IL-6 + IL-23 (Th22 priming condition) or IL-6 + IL-23 + TGF-β (Th17 priming condition) (**Fig 1A**). IL-22 protein production in supernatants of primary cell cultures was also elevated by PGE₂ in the presence of IL-23 or IL-23 + IL-6 (**Fig 1B**). It is important to note that these data are in agreement with previous findings³⁷ that TGF-β inhibits IL-22 production even in the presence of PGE₂ (Fig 1A,B). Moreover, when same numbers of PGE₂-stimulated T-cells and control T-cells were washed and then re-stimulated with T-cell receptors (i.e. anti-CD3 and anti-CD28), PGE₂-stimulated T-cells produced more IL-22 than control T-cells even in the presence of TGF-β (**Fig 1C**), suggesting that PGE₂-treated cells have higher capability to produce IL-22 at the single cell level.

To define which PGE₂ receptor mediates IL-22 production, we cultured T-cells under Th22-priming conditions and selectively activated EP2 and EP4. Both EP2 and EP4 agonists individually mimicked augmentation of IL-22 production (**Fig 1D**). To further confirm the roles of PGE₂-EP2/EP4 signaling in inducing IL-22 production of T-cells, we also cultured differentiated Th17 T-cells and found that PGE₂ still promotes IL-23-driven IL-22 gene and protein expression (**Fig 1E and 1F**). Moreover, enhancement of IL-22 production by EP2 or EP4 agonists was prevented by co-treatment of antagonists against EP2 or EP4, respectively (**Fig 1F**); elevated IL-22 production by PGE₂ was also diminished by co-administration of

EP2 and EP4 antagonists (**Fig 1F**). In addition, PGE₂ also increased IL-22 production in Th17 cells in the absence of other cytokines (**Fig 1E and 1F**), suggesting a potentially direct action of PGE₂ to promote *Il22* gene expression. These data indicate the involvement of EP2 and EP4 in PGE₂ facilitation of IL-22 production from T cells *in vitro*.

Cyclic AMP promotes IL-22 production from T cells through the transcription factor aryl hydrocarbon receptor (AHR).

As both EP2 and EP4 receptors activate cAMP-PKA pathway in T cells²⁶, we next examined whether cAMP mediates PGE₂ facilitation of adaptive IL-22 production. Like PGE₂, db-cAMP promoted IL-22 production in a concentration-dependent manner in either presence or absence of IL-23 (**Fig 2A**), confirming a direct action of cAMP on IL-22 induction. The increased IL-22 production by cAMP was prevented by PKI, a PKA inhibitor, in a concentration-dependent manner (**Fig 2B**). Cyclic AMP also up-regulated *Il22* gene expression in IL-23-stimulated T-cells, which was prevented by cycloheximide, an inhibitor for eukaryote protein synthesis (**Fig 2C and 2D**), suggesting that the PGE₂-cAMP pathway promoted adaptive IL-22 production through synthesis of new protein(s).

The transcription factor AHR has been reported to regulate IL-22 production in both T-cells and ILC3s²⁹. We thus investigated whether AHR contributes to PGE₂-cAMP signaling-dependent increase in adaptive IL-22 production. We first checked that both PGE₂ and cAMP up-regulated *AHR* gene expression in T-cells independently of cytokine stimuli (**Fig 2E and 2F**). Importantly, a small-molecule AHR inhibitor CH-223191 effectively suppressed cAMP-dependent IL-22 gene expression and protein production from T cells (**Fig 2G and 2H**) although it had no effect on AHR expression itself (**Fig 2F**). These results suggest that PGE₂-cAMP signaling promotes IL-22 production from T-cells through induction of AHR.

PGE₂-EP4 signaling promotes adaptive IL-22 production *in vivo*

To investigate whether PGE₂ promotes adaptive IL-22 production *in vivo*, we topically sensitized the abdominal skin of control mice and mice with specific EP4 deletion in T cells (EP4cKO mice²⁷) with DNFB and measured IL-22-producing T-cells in skin-draining LNs 5 days after sensitization using flow cytometry. Both percentages and absolute numbers of IL-22-producing T-cells were markedly reduced in EP4cKO compared to control mice (**Fig 3A and 3B**). Furthermore, EP4 deficiency reduced *Il22* gene expression in skin-draining LN CD4⁺ T cells (**Fig 3C**). These data indicate that PGE₂-EP4 signaling promotes adaptive IL-22 production *in vivo*.

Endogenous PGE₂-EP4 signaling in T cells promotes allergic contact dermatitis

We next investigated whether PGE₂ has a pathogenic role in development of allergic skin inflammation. To address this question, we used an animal model mimicking human ACD. We sensitized wild-type C57BL/6 mice with 3% oxalozone (OXA) on abdominal skin and after 5 days we repeatedly challenged mice with 0.6% OXA every two days for a total of 5 challenges. Indomethacin was administered to mice in drinking water to inhibit endogenous PGE₂ production. Once DCs in the skin capture the antigen OXA, they migrate to skin dLNs and present antigen to T cells for their activation. Because the migration of antigen-capturing DCs to skin dLNs peaks between 18-24h requires PGE₂-EP4 signaling³⁸, we only treated mice with indomethacin 24 h post the OXA sensitization (**Fig 4A**). Consistent with previous reports¹¹, repeated challenge with OXA induced allergic skin inflammation (**Fig 4B and 4C**). Ears of OXA-challenged, indomethacin-treated mice showed decreased swelling compared to vehicle-treated mice (**Fig 4B**). Indomethacin had no effect on the thickness of vehicle (EtOH)-challenged ears. Compared to EtOH-challenged ears, histology of OXA-challenged

ear skin showed features of eczema, namely parakeratosis, acanthosis and focal spongiosis with a dense and diffuse dermal infiltrate containing eosinophils (**Fig 4C**). However, in skin from the indomethacin-treated mice the epidermal changes are less pronounced, and the dermal infiltrates are markedly reduced (**Fig 4C**). Furthermore, whilst repeated OXA challenge recruited CD4⁺ and CD8⁺ T cells to ear-draining LNs (**Fig 4D**), indomethacin treatment reduced both this recruitment and the T-cell capacity to produce IL-22 (**Fig 4E**). To further investigated whether this pro-inflammatory effect of PGE₂ on OXA-induced ACD development was mediated by EP4 and T cells, we performed this model on EP4cKO and control (EP4^{fl/fl}) mice. OXA induced significantly less ear skin inflammation in EP4cKO mice compared to control mice (**Fig. 4F**), suggesting that PGE₂-EP4 signaling in T cells promotes ACD development.

PGE₂-dependent IL-22 production and signaling in human atopic lesional skin

We next investigated whether PGE₂-dependent adaptive IL-22 production and signaling can be found in human atopic skin. We analyzed mRNA expression of genes related to PGE₂ metabolism (**Fig 5A**) and IL-22 signaling pathways in human lesional AD and normal skin biopsies. As reported previously³², mRNA expression levels for Th17/Th22 related genes (*IL17A*, *IL22*, *IL23R*, *AHR*), IL-22-induced products (e.g. *S100A7*, *S100A8*, *S100A9*), and skin-homing chemokines (*CCR4*) were over-expressed in lesional AD compared to normal skin (**Fig 5B**). Strikingly, mRNA expression levels for PGE₂ synthases (*PTGS2*, *PTGES*, *PTGES2*) were also up-regulated in human atopic lesional skin, and expression levels for the PGE₂ degradation enzyme *HPGD* (hydroxyprostaglandin dehydrogenase 15-(NAD)) was in contrast down-regulated in lesional AD skin (**Fig 5B**). These gene expression data are consistent with previous reports showing increased PGE₂ levels in lesional AD skin²¹. There was a trend that expression of *PTGER4* gene (encoding PGE₂ receptor EP4) was up-regulated

in lesional AD skin, but expression of *PTGER2* (encoding PGE₂ receptor EP2) was significantly down-regulated in lesional AD skin (Fig. 5B). Expression of Th2 cytokines (e.g. IL4, IL5, IL13) were not significantly up-regulated in lesional AD skin, however Th2 chemokines such as *CCL26*, *CCL18*, *CCL22*, *CCL17*, *CCL11* and *CCL5* were up-regulated in lesional AD skin compared to normal skin (**Fig 5B**). Interestingly, expression of IL-22 pathway genes showed strongly positive correlation with those of *PTGES* in biopsy samples from lesional AD but not normal skin (**Fig 5C**). There were no correlations between *PTGES* expression and Th2 cytokines (data not shown). However, weak correlations between *PTGES* gene expression and Th2 chemokines in lesional AD skin were observed (**Fig 5D**). These results suggest that PGE₂ signaling is activated and positively correlates with the IL-22 signaling pathway and, probably, the Th2 pathway in human atopic skin.

Finally, we investigated whether current therapies for atopic dermatitis modulate PGE₂ signaling in human AD. We analyzed changes in expression levels of IL-22 and PGE₂ signaling genes in lesional AD skin before and after treatments such as betamethasone (a corticosteroid) by re-analyzing a public microarray dataset³⁴. Compared to baseline levels, treatments with betamethasone reduced *IL22* gene expression in atopic lesional skin. Betamethasone also significantly reduced expression of IL-22-related genes such as *AHR*, *SI00A8*, *SI00A9* (**Fig 6A**). Expression of PGE₂ synthases (e.g. *PTGES*, *PTGES2*) and *EP4* receptor (*PTGER4*) was significantly downregulated by betamethasone treatment, while EP2 receptor (*PTGER2*) expression was not changed (**Fig 6A**). This observation is consistent with findings that betamethasone treatment reduces PGE₂ production^{39,40}. Interestingly, expression of *PTGES*, *PTGES2* and *PTGER4*, but not *PTGER2*, positively correlated with *IL22* expression in atopic biopsies at baseline, while expression of *HPGD*, which mediates PGE₂ degradation, negatively correlated with *IL22* expression (**Fig 6B**). Furthermore, we have also

reanalyzed gene expression of skin biopsies before and after treated with UVB from our previous dataset³⁵. Expression of PGE₂ synthases *PTGS1* and *PTGES* in lesional AD skin were down-regulated after treatment with UVB (**Fig 6C**). Interestingly, although IL-22 gene expression was not changed by UVB treatment, most likely due to the small number of samples, changes in expression of IL-22 activated genes (e.g. *S100A8* and *S100A9*) positively correlated with changes in expression of PGE₂ synthases (i.e. *PTGS1*, *PTGES* and *PTGES2*) in atopic lesional, but not in non-lesional biopsies (**Fig 6D and data not shown**). Together, these data indicate that PGE₂, most likely through the EP4 receptor, plays a role in IL-22 regulation in human skin.

Discussion

The cytokine IL-22, notably produced by Th22 and Th17 T-cells, is emerging as a key player in AD^{3,12,16}, leading to a new therapy targeting IL-22 signaling in AD clinical trials (NCT01941537). Genome-wide association studies have identified that gene polymorphisms of the PGE₂ receptor EP4 were associated with T cell-mediated human autoimmune and allergic inflammatory diseases^{41,42}. However, the role of PGE₂ in promoting IL-22 production and development of AD remain to be determined. Therefore, in this study, we examined this using *in vitro* cell cultures and *in vivo* ACD mouse model as well as interrogating gene expression in human AD lesional skin before and after common treatments for AD.

We show that PGE₂ markedly stimulates IL-22 production from T-cells, which complements our previous findings that PGE₂ promotes innate IL-22 production from ILC3s²⁸. It is worth noting that PGE₂ promotes IL-22 production from freshly activated CD4⁺ T-cells under various conditions including Th17 and Th22-priming conditions. The effect of PGE₂ was mimicked by activation of EP2 and EP4 receptors and was prevented by antagonists against these receptors, confirming the involvement of these two receptors in adaptive IL-22 production *in vitro*. Further studies showed that the cAMP-PKA signaling pathway, activated by engagement of EP2 and EP4, mediates PGE₂ enhancement of IL-22 production through induction of newly expressed AHR. Our results thus uncover a new, targetable molecular mechanism for regulation of adaptive IL-22 by the PGE₂-cAMP-AHR axis.

The role of PGE₂ in promoting adaptive IL-22 production was also confirmed *in vivo*. T-cell specific EP4 deficiency led to large reduction of IL-22⁺ T-cells in skin-draining LNs in response to hapten sensitization and attenuated repeated OXA challenge-induced allergic skin inflammation in the mouse model of ACD, indicating a critical role of endogenous EP4

signaling in T-cells for IL-22 expression and function *in vivo*. This is similar to innate IL-22 expression which also requires PGE₂-EP4 signaling²⁸, suggesting a shared mechanism for regulating both the adaptive and innate IL-22 responses. Inhibition of endogenous PGE₂ production by a COX inhibitor successfully prevented accumulation of T-cells in ear-draining LNs, reduced T-cell production of IL-22 and attenuated allergic skin inflammation induced by repeated OXA challenges. Given that PGE₂ also promotes IL-17 production from both mouse and human Th17 T-cells^{26,43} and that IL-17 may participate in creating the ACD phenotype⁹⁻¹², IL-17 may also be involved in the PGE₂-facilitated ACD pathogenesis.

Facilitation of IL-22 production by PGE₂ may contribute to several human inflammatory diseases such as AD and psoriasis⁴⁴. Indeed, parallel up-regulations of IL-22 pathway genes, PGE₂ synthases were observed in human atopic lesional skin, whereas the PGE₂ degrading enzyme 15-PGDH (encoded by *HPGD*) was down-regulated in AD skin. This is consistent with previous observations showing increased PGE₂ levels in lesional AD skin²². Moreover, our data indicate that IL-22 signaling positively correlated with PGE₂ signaling in atopic lesional skin, and these correlations were absent in both normal skin or in lesional AD skin following successful steroid or UVB treatments. These findings potentially suggest a PGE₂-dependent IL-22 production and signaling in human atopic skin.

Besides IL-22⁺ T-cells, Th2 cells (especially cutaneous lymphocyte antigen-positive population with skin-homing capacity) are expanded in severe AD⁴⁵. Th2 cells suppress major terminal differentiation proteins (i.e. filaggrin and loricrin) and predominates in the acute phase of AD through production of cytokines (e.g. *IL4* and *IL13*) and chemokines (e.g. *CCL17*, *CCL18*, *CCL26*, etc)^{33,46}. The Th2 response is thus critical for AD pathogenesis. Inhibition of COX2 has been reported to enhance Th2 cytokine production and Th2 response

to ovalbumin-induced epicutaneous sensitization²³, suggesting a potential inhibitory role of PGs in Th2 cell-driven allergic inflammation. In human lesional AD skin, however, there was no correlations between the PGE₂ pathway and Th2 cytokines and, in contrast, weak positive correlations between the PGE₂ pathway and Th2 chemokines, suggesting a possible promoting role of PGE₂ in Th2 response in AD. This may be because PGE₂ promotes IL-17 and IL-22 production^{26-28,42} and subsequently IL-17 exacerbates Th2 type inflammation during the initiation of AD^{11,47}.

We acknowledge this report has several limitations. For example, our analysis of gene expression profiles in human skin biopsies were retrieved from public GEO datasets and confirmation of these findings was not performed by methods with higher sensitivity such as real-time PCR using fresh biopsies. Moreover, cytokine expression in protein levels in different T-cell subsets were not measured by flow cytometry in skin of patients and animals. Furthermore, although in mice, the OXA-repeated challenge-induced chronic allergic skin inflammation represents a robust model, additional animal models are required in attempt to fully mimic most pathogenic and physiologic processes during the development of human AD. In addition, due to limitation of resources, the effects of PGE₂ signaling in T cells, especially the involvement of both EP2 and EP4 in T cells, on initiation and progression of ACD could not be interrogated, e.g. using mice with T cell-specific deficiency of both EP2 and EP4 receptors. Future prospective studies are therefore required to further understand not only the role of PGE₂ during perpetuating AD skin inflammation but also during its onset.

In conclusion, our data ascertain that PGE₂ acts as a potent promoter of both adaptive and innate IL-22 production. We have previously found that PGE₂ signaling promotes DC production of IL-23, a cytokine essential for IL-22 expression, as well as for proliferation and

468 maturation of Th17 T-cells²⁶. Taken together, our results highlight the PGE₂ signaling
469 pathway as an important stimulus of T-cell responses and AD development. Thus targeting
470 PGE₂ synthesis or its receptors may represent a possible therapeutic strategy for the treatment
471 of AD, and other inflammatory skin diseases such as psoriasis with an active role for IL-22,
472 such as psoriasis.
473

References

1. Bieber T. Atopic Dermatitis. *N Engl J Med* 2008;358:1483-94.
2. Malajian D, Guttman-Yassky E. New pathogenic and therapeutic paradigms in atopic dermatitis. *Cytokine* 2015 Jun;73(2):311-8.
3. Noda S, Krueger JG, Guttman-Yassky E. The translational revolution and use of biologics in patients with inflammatory skin diseases. *J Allergy Clin Immunol* 2015;135:324-36.
4. Gittler JK, Krueger JG, Guttman-Yassky E. Atopic dermatitis results in intrinsic barrier and immune abnormalities: implications for contact dermatitis. *J Allergy Clin Immunol*. 2013;131:300-313.
5. Cork MJ, Danby SG, Vasilopoulos Y, Hadgraft J, Lane ME, Moustafa M. Epidermal barrier dysfunction in atopic dermatitis. *J Invest Dermatol* 2009;129:1892-908.
6. Egawa G, Kabashima K. Multifactorial skin barrier deficiency and atopic dermatitis: Essential topics to prevent the atopic march. *J Allergy Clin Immunol* 2016;138:350-8.
7. Kabashima K. New concept of the pathogenesis of atopic dermatitis: interplay among the barrier, allergy, and pruritus as a trinity. *J Dermatol Sci* 2013;70:3–11.
8. Romagnani S. Immunologic influences on allergy and the TH1/TH2 balance. *J Allergy Clin Immunol* 2004;113:395–400.
9. Guttman-Yassky E, Lowes MA, Fuentes-Duculan J, Zaba LC, Cardinale I, Nogales KE, et al. Low expression of the IL-23/Th17 pathway in atopic dermatitis compared to psoriasis. *J Immunol* 2008;181:7420–7.
10. Eyerich K, Pennino D, Scarponi C, Foerster S, Nasorri F, Behrendt H, et al. IL-17 in atopic eczema: linking allergen-specific adaptive and microbial-triggered innate immune response. *J Allergy Clin Immunol* 2009;123:59–66.
11. Nakajima S, Kitoh A, Egawa G, Natsuaki Y, Nakamizo S, Moniaga CS, et al. IL-17A as

- 499 an inducer for Th2 immune responses in murine atopic dermatitis models. *J Invest*
500 *Dermatol* 2014;134:2122–30.
- 501 12. Souwer Y, Szegedi K, Kapsenberg ML, de Jong EC. IL-17 and IL-22 in atopic allergic
502 disease. *Curr Opin Immunol*, 2010;22:821–6.
- 503 13. Czarnewicki T, Krueger JG, Guttman-Yassky E. Skin barrier and immune dysregulation
504 in atopic dermatitis: an evolving story with important clinical implications. *J Allergy*
505 *Clin Immunol Pract*. 2014;2:371-379.
- 506 14. Hayashida S, Uchi H, Takeuchi S, Esaki H, Moroi Y, Furue M, et al. Significant
507 correlation of serum IL-22 levels with CCL17 levels in atopic dermatitis. *J Dermatol Sci*
508 2011;61:78-9.
- 509 15. Ungar B1, Garcet S2, Gonzalez J2, Dhingra N1, da Rosa JC2, Shemer A3, et al. An
510 integrated model of atopic dermatitis biomarkers highlights the systemic nature of the
511 disease. *J Invest Dermatol*. 2016;4: S0022-202X(16)32620-3.
- 512 16. Nograles KE, Zaba LC, Shemer A, Fuentes-Duculan J, Cardinale I, Kikuchi T, et al. IL-
513 22-producing “T22” T cells account for upregulated IL-22 in atopic dermatitis despite
514 reduced IL-17-producing TH17 T cells. *J Allergy Clin Immunol* 2009;123:1244–52.
- 515 17. Nograles KE, Suárez-Fariñas M, Shemer A, Fuentes-Duculan J, Chiricozzi A, Cardinale
516 I, et al. Atopic dermatitis keratinocytes exhibit normal T(H)17 cytokine responses. *J*
517 *Allergy Clin Immunol*. 2010;125:744-746.
- 518 18. Boniface K, Bernard FX, Garcia M, Gurney AL, Lecron JC, Morel F, et al. IL-22
519 inhibits epidermal differentiation and induces proinflammatory gene expression and
520 migration of human keratinocytes. *J Immunol* 2005;174:3695–702.
- 521 19. Guttman-Yassky E, Ungar B, Noda S, Suprun M, Shroff A, Dutt R, et al. Extensive
522 alopecia areata is reversed by IL-12/IL-23p40 cytokine antagonism. *J Allergy Clin*
523 *Immunol*. 2016;137:301-304.

20. Hirata T, Narumiya S. Prostanoids as regulators of innate and adaptive immunity. *Adv Immunol* 2012;116:143-74.
21. Honda T, Kabashima K. Prostanoids in allergy. *Allergology International* 2015;64:11-16.
22. Fogh K, Herlin T, Kragballe K. Eicosanoids in skin of patients with atopic dermatitis: prostaglandin E₂ and leukotriene B₄ are present in biologically active concentrations. *J Allergy Clin Immunol* 1989;83:450-5.
23. Laouini D, Elkhail A, Yalcindag A, Kawamoto S, Oettgen H, Geha RS, et al. COX-2 inhibition enhances the T_H2 immune response to epicutaneous sensitization. *J Allergy Clin Immunol* 2005;116:390-6.
24. Chan S, Henderson WR Jr, Li SH, Hanifin JM. Prostaglandin E₂ control of T cell cytokine production is functionally related to the reduced lymphocyte proliferation in atopic dermatitis. *J Allergy Clin Immunol* 1996;97:85-94.
25. Fedyk ER, Phipps RP. Prostaglandin E₂ receptors of the EP2 and EP4 subtypes regulate activation and differentiation of mouse B lymphocytes to IgE-secreting cells. *Proc Natl Acad Sci U S A* 1996;93:10978-83.
26. Yao C, Sakata D, Esaki Y, Li Y, Matsuoka T, Kuroiwa K, et al. Prostaglandin E₂-EP4 signaling promotes immune inflammation through Th1 cell differentiation and Th17 cell expansion. *Nat Med* 2009;15:633-40.
27. Yao C, Hirata T, Soontrapa K, Ma X, Takemori H, Narumiya S. Prostaglandin E₂ promotes Th1 differentiation via synergistic amplification of IL-12 signalling by cAMP and PI3-kinase. *Nat Commun* 2013;4:1685.
28. Duffin R, O'Connor RA, Crittenden S, Forster T, Yu C, Zheng X, et al. Prostaglandin E₂ constrains systemic inflammation through an innate lymphoid cell-IL-22 axis. *Science*. 2016;351:1333-8.
29. Cella M, Colonna M. Aryl hydrocarbon receptor: Linking environment to immunity.

- 549 Semin Immunol 2015;27:310-4.
- 550 30. Schneider A, Guan Y, Zhang Y, Magnuson MA, Pettepher C, Loftin CD et al.
551 Generation of a conditional allele of the mouse prostaglandin EP4 receptor. Genesis
552 2004;40:7–14.
- 553 31. Guttman-Yassky E, Suárez-Fariñas M, Chiricozzi A, Nograles KE, Shemer A, Fuentes-
554 Duculan J, et al. Broad defects in epidermal cornification in atopic dermatitis identified
555 through genomic analysis. J Allergy Clin Immunol 2009;124:1235-44.
- 556 32. Suárez-Fariñas M, Tintle SJ, Shemer A, Chiricozzi A, Nograles K, Cardinale I, et al.
557 Nonlesional atopic dermatitis skin is characterized by broad terminal differentiation
558 defects and variable immune abnormalities. J Allergy Clin Immunol 2011;127:954-64.
- 559 33. Gittler JK, Shemer A, Suárez-Fariñas M, Fuentes-Duculan J, Gulewicz KJ, Wang CQ, et
560 al. Progressive activation of T(H)2/T(H)22 cytokines and selective epidermal proteins
561 characterizes acute and chronic atopic dermatitis. J Allergy Clin Immunol
562 2012;130:1344-54.
- 563 34. Jensen JM, Scherer A, Wanke C, Bräutigam M, Bongiovanni S, Letzkus M, et al. Gene
564 expression is differently affected by pimecrolimus and betamethasone in lesional skin of
565 atopic dermatitis. Allergy 2012;67:413-23.
- 566 35. Tintle S, Shemer A, Suárez-Fariñas M, Fujita H, Gilleaudeau P, Sullivan-Whalen M, et
567 al. Reversal of atopic dermatitis with narrow-band UVB phototherapy and biomarkers
568 for therapeutic response. J Allergy Clin Immunol 2011;128:583-93.
- 569 36. Cheadle C, Vawter MP, Freed WJ, Becker KG. Analysis of Microarray Data Using Z
570 Score Transformation. J Mol Diagn, 2003;5:73-81.
- 571 37. Rutz S, *et al.* Transcription factor c-Maf mediates the TGF- β -dependent suppression of
572 IL-22 production in TH17 cells. Nat Immunol, 2011;12:1238-1245.
- 573 38. Kabashima K, Sakata D, Nagamachi M, Miyachi Y, Inaba K, Narumiya S. Prostaglandin

- 574 E₂-EP4 signaling initiates skin immune responses by promoting migration and
575 maturation of Langerhans cells. *Nat Med* 2003;9:744-9.
- 576 39. Inada T, Kushida A, Sakamoto S, Taguchi H, Shingu K. Intrathecal betamethasone pain
577 relief in cancer patients with vertebral metastasis: a pilot study. *Acta Anaesthesiol Scand*.
578 2007;51:490-494.
- 579 40. Zulfakar MH, Abdelouahab N, Heard CM. Enhanced topical delivery and ex vivo anti-
580 inflammatory activity from a betamethasone dipropionate formulation containing fish
581 oil. *Inflamm Res*. 2010;59:23-30.
- 582 41. Kurz T, Hoffjan S, Hayes MG, Schneider D, Nicolae R, Heinzmann A, et al. Fine
583 mapping and positional candidate studies on chromosome 5p13 identify multiple asthma
584 susceptibility loci. *J Allergy Clin Immunol* 2006;118:396-402.
- 585 42. Hinds DA, McMahon G, Kiefer AK, Do CB, Eriksson N, Evans DM, et al. A genome-
586 wide association meta-analysis of self-reported allergy identifies shared and allergy-
587 specific susceptibility loci. *Nat Genet*. 2013;45:907-11.
- 588 43. Boniface K, Bak-Jensen KS, Li Y, Blumenschein WM, McGeachy MJ, McClanahan TK,
589 et al. Prostaglandin E₂ regulates Th17 cell differentiation and function through cyclic
590 AMP and EP2/EP4 receptor signaling. *J Exp Med* 2009;206:535-48.
- 591 44. Noda S, Suárez-Fariñas M, Ungar B, Kim SJ, de Guzman Strong C, Xu H, et al. The
592 Asian atopic dermatitis phenotype combines features of atopic dermatitis and psoriasis
593 with increased TH17 polarization. *J Allergy Clin Immunol*. 2015;136:1254-1264.
- 594 45. Czarnowicki T, Gonzalez J, Shemer A, Malajian D, Xu H, Zheng X, et al. Severe atopic
595 dermatitis is characterized by selective expansion of circulating TH2/TC2 and
596 TH22/TC22, but not TH17/TC17, cells within the skin-homing T-cell population. *J*
597 *Allergy Clin Immunol*. 2015;136:104-115.
- 598 46. Sehra S, Yao Y, Howell MD, et al. IL-4 regulates skin homeostasis and the

- 599 predisposition toward allergic skin inflammation. *J Immunol* 2010;184:3186-90.
- 600 47. Dhingra N, Guttman-Yassky E. A possible role for IL-17A in establishing Th2
- 601 inflammation in murine models of atopic dermatitis. *J Invest Dermatol.* 2014;134:2071-
- 602 2074.
- 603

Figure Legends**Figure 1. PGE₂ promotes T cell production of IL-22 through its receptors EP2 and EP4.**

A, *Il22* mRNA expression in naïve CD4⁺ T cells stimulated with anti-CD3 and anti-CD28 (anti-CD3/CD28) antibodies (Abs) with indicated cytokines in the absence or presence of PGE₂ (100 nM) for 3 days. **B**, IL-22 levels in supernatants of cultures in A. **C**, IL-22 levels in supernatants of naïve CD4⁺ T cells were cultured as in A and then the same numbers of T cells were re-stimulated with anti-CD3/CD28 Abs for another 3 days. **D**, IL-22 levels in supernatants of naïve CD4⁺ T cells were stimulated with anti-CD3/CD28 Abs with IL-6+IL-23 with or without an EP2 agonist (butaprost, 1 µM) or EP4 agonist (L-902,688, 1 µM) for 3 days and then the same numbers of T cells were re-stimulated with anti-CD3/CD28 Abs for another 3 days. **E**, IL-22 levels in supernatants from Th17 cells re-stimulated with anti-CD3/CD28 Abs without or with IL-23 and various small molecule compounds activating or inhibiting PGE₂ receptors for 3 days. **F**, *Il22* mRNA of re-stimulated Th17 cells with PGE₂ and/or IL-23 for 3 days. EP1/3 agonist 17-phenyl trinor PGE₂ was used at 1 µM while EP2 antagonist PF-04418948 and EP4 antagonist L-161,982 were used at 10 µM. All experiments were performed in duplicates or triplicates and repeated for 2-3 times independently. **P*<0.05, ***P*<0.01, ****P*<0.001 and *****P*<0.0001.

Figure 2. Cyclic AMP promotes IL-22 production from T cells through induction of aryl

hydrocarbon receptor (Ahr). **A**, IL-22 levels in supernatants from Th17 cells re-stimulated with anti-CD3/CD28 Abs without or with IL-23 and indicated concentrations of db-cAMP for 3 days. **B**, IL-22 levels in supernatants from Th17 cells re-stimulated with anti-CD3/CD28 Abs with IL-23, db-cAMP (100 µM) and indicated concentrations of PKI for 3 days. **C,D**, *Il22* mRNA expression levels in Th17 cells re-stimulated with anti-CD3/CD28 Abs with IL-23 and db-cAMP in the absence (C) or presence (D) of cycloheximide (CHX, 1

μM) for 3 days. **E**, *Ahr* mRNA expression in naïve CD4⁺ T cells cultured with anti-CD3/CD28 Abs and indicated cytokines in the absence or presence of PGE₂ for 3 days. **F-H**, *Ahr* (F) and *Il22* (G) mRNA expression and IL-22 levels (H) in supernatants of Th17 cells cultured with anti-CD3/CD28 Abs, IL-23, db-cAMP and CH-223191 (10 μM) for 3 days. All experiments were performed in duplicates or triplicates and repeated for 2-3 times independently. **P*<0.05, ***P*<0.01, ****P*<0.001 and *****P*<0.0001. ns, non significant.

Figure 3. PGE₂-EP4 signaling in T cells facilitates IL-22 production *in vivo*. **A**, Representative flow cytometry dot-plot of IL-22 and IL-17 expression in skin-draining LN CD4⁺ T cells from T cell-specific EP4 deficient (EP4cKO, n=9) mice or control mice (n=10) 5 days post sensitization with 0.5% DNFB. **B**, Percentages and numbers of IL-22⁺ CD4⁺ T cells. Each dot represents one mouse. **C**, *Il22* mRNA expression levels in CD4⁺ T cells isolated from skin-draining LNs of EP4cKO (n=6) or control (n=6) mice. Each dot represents one mouse. **P*<0.05.

Figure 4. PGE₂ exacerbates atopic skin inflammation in the repeated oxalozone (OXA) challenge model. **A-E**, WT C57BL/6 mice were sensitized with 3% OXA on abdominal skin on (day 0) and then challenged with 0.6% OXA or EtOH on ears 5 days later. Challenge with OXA was repeated once every two days for a total of 5 challenges. Ears and ear-draining LNs were collected 6 h after the last OXA challenge (n=4-5). **A**, Schematic representation of the experimental protocol. **B**, Ear thickness. **C**, Ear histology. Scale bar, 50 μM. **D**, CD4⁺ and CD8⁺ T cells in ear-draining LNs. **E**, IL-22 production by ear-draining LN cells cultured with soluble anti-CD3 or medium only *in vitro* for 3 days. **F**, Swelling of ears from control and EP4cKO mice (n=9-13) sensitized and repeatedly challenged with OXA as in **A** but without indomethacin treatment. **P*<0.05; ****P*<0.001 and *****P*<0.0001.

Figure 5. Over-expression of PGE₂ signaling genes in human lesional AD skin which positively correlate with expression of IL-22 signaling genes. **A**, Schematic depicting synthesis and metabolism of PGE₂ mediated by COX2 (encoding by *PTGS2*), PGE synthases (encoding by *PTGES* or *PTGES2*) and 15-PGDH (encoding by *HPGD*), respectively. A PGE₂ receptor EP4 (encoding by *PTGER4*) is also shown. **B**, Heat map of expression profiles of Th2 cytokine and chemokine genes and genes related to IL-22 and PGE₂ pathways in human lesional AD skin (n=38) and normal skin (n=32). A color scale bar indicates the Z-score transformed values of microarray gene expression data³¹⁻³³. Z-ratios represent the changes in gene expression levels between the normal and AD lesional groups³⁶. *P* values were calculated by nonparametric Wilcoxon-Mann-Whitney tests. Probes with the largest Z-ratios were chosen when several probes represented single genes. **C,D**, Correlations of *PTGES* gene expression versus expression of IL-22 pathway genes (**C**) or Th2 chemokines (**D**) in atopic lesional and normal skins. *P* value was calculated by nonparametric Spearman correlation test.

Figure 6. Steroid and UVB therapies down-regulate PGE₂ and IL-22 signaling pathway genes in human atopic lesional skin. **A**, Expression profiles of genes related to PGE₂ and IL-22 pathways in human lesional AD skin (n=10) at baseline (AD Base) or after treatment with betamethasone for 3 weeks. The z-score transformed values of microarray gene expression data³⁴ were used. *P* value was calculated by paired nonparametric tests with post-hoc Dunn's multiple comparisons test. **B**, Correlations of *PTGES*, *PTGES2*, *HPGD*, *PTGER4* gene expression versus that of *IL22* gene in human atopic lesional skins at baseline. *P* value was calculated by nonparametric Spearman correlation test. **C**, Expression of genes related to PGE₂ and IL-22 signaling in human atopic lesional (AL, n=8) and non-lesional (ANL, n=7)

679 skin before (PRE) or 12 weeks after (POST) treatment with UVB. The z-score transformed
680 values of microarray gene expression data³⁵ were used. *P* value was calculated by paired 2-
681 way ANOVA test with post-hoc Bonferroni's multiple comparisons. **D**, Correlations of
682 changes in expression of IL-22-induced genes (*S100A8*, *S100A9*) and PGE₂ synthase genes
683 (*PTGS1*, *PTGES* and *PTGES2*) before (PRE) and after (POST) UVB therapy in atopic AL or
684 NL skins. *P* value was calculated by nonparametric Spearman correlation test.

685

Fig.1




Fig. 2





Fig. 3

Fig. 4




Fig. 5




Fig. 6

